BioCentury
ARTICLE | Clinical News

Trelstar triptorelin pamoate regulatory update

March 22, 2010 7:00 AM UTC

FDA approved a 6-month formulation of 22.5 mg Trelstar triptorelin pamoate from Watson for palliative treatment of advanced prostate cancer. The company plans to launch the product in May. Watson alre...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article